Tackling osteosarcoma in people and pet dogs

December 13, 2016 by Kendall Morgan
Pictured on the NCSU campus are members of the Duke-NC State team (from left) Joanne Tuohy, Duncan Lacelles, Jason Somarelli, Jonathan Fogle, and Will Eward. Credit: Nathan Latil, NCSU Biomedical Communications

Dogs and people have lived side-by-side for thousands of years. So it should come as no surprise that dogs and their people have much in common. Unfortunately, the shared experiences of our two species include a considerable risk of developing cancer at some point in our lives. In fact, dogs and people often suffer from cancers that are remarkably similar at the biological level. Take osteosarcoma, for example, a devastating form of bone cancer.

"Osteosarcoma is a great example of a disease that's exactly the same in a dog as it is in a person," said William Eward , an orthopedic cancer surgeon at Duke. "If you took osteosarcoma from a dog and a person and you didn't know which species it came from, you could not tell the two apart. You couldn't tell them apart from looking at the tumor with the naked eye. You couldn't tell under a microscope using various stains. You couldn't tell them apart even by running an RNA analysis in the lab."

In humans, osteosarcoma most often strikes teens and sometimes kids even younger. In , osteosarcoma is most common in large and giant breeds, such as Great Danes, Rottweilers and Saint Bernards. There hasn't been any notable progress in the treatment and survival of human or dog patients with osteosarcoma in the last 30 years.

The statistics are grim: Only 70 percent of people with osteosarcoma survive for five years after their diagnosis. Most dogs don't make it for more than a year. With support from a Duke/NC State Translational Research Grant from the Duke Clinical & Translational Science Institute, Eward and colleague Jonathan Fogle , a veterinary immunologist at NC State, are working to improve those odds for people and their pets by capitalizing on aspects of the disease that are unique to canines.

"Dogs get osteosarcoma more often [than people do]," Fogle said. "That's a plus because we have more patients to study. The lifespan of dogs is also shorter in general and the progression of their disease more rapid. That gives us the ability to study not only the behavior of the cancer but also interventions and outcomes in a shorter period of time."

Wake Up and Fight

Eward and Fogle are focusing their attention on a phenomenon that's as peculiar as it is promising: after surgical procedures to remove osteosarcoma, dogs and people are more likely to survive the cancer for longer if their surgical wounds subsequently become infected. As Fogle explains it, osteosarcoma cells most likely manage to persist and spread in part by suppressing the . As a result, fail to recognize the cancerous tumor cells as a threat and they don't fight against them. If, however, an infection causes inflammation that spurs the immune system into action, it seems to compromise that arrangement between the immune cells and the cancer.

"Infection and inflammation might switch the immune response from a tolerant one to one that recognizes the tumor and responds with a heightened immune response," Fogle said. "We think the inflammation is somehow waking up the immune system."

Eward, Fogle and their colleagues already have some evidence in support of this idea based on preliminary studies they've conducted in mouse models and cells in the lab. They've now proposed a series of experiments designed to further explore the role of small snippets of RNA called microRNA in shifting the immune system, and specifically immune cells called macrophages, between these more and less tolerant states.

To explore this possibility in the new work, the researchers will culture healthy dog macrophages with osteosarcoma cells to find out whether it leads macrophages to shift gears in the expected way. They'll be making comparisons between the microRNA profiles within macrophages isolated from human and dog osteosarcoma samples. They'll also examine how exposure to bacteria changes both the microRNA profiles and macrophage behavior and whether it's possible to override those effects using molecules that mimic or block particular microRNA molecules.

If all goes well, the researchers say the next logical step is to seek funding for clinical trials of a treatment targeting the immune system via microRNA, to be conducted first in canine patients.

"If it works in dogs or if the concept seems promising, then the next logical step is to apply the same techniques in human patients," Fogle said.

Tearing Down the Silos

Despite the strong similarities between many human and animal diseases, most veterinarians and human doctors haven't been in the habit of working together. Veterinary medicine and human medicine are typically practiced in isolation, with little connection between the two. But the collaboration comes rather naturally to this Duke-NC State team. In fact, before Eward went to medical school, he was trained as a veterinarian. His plan was never to leave , but to do both.

As it happens, Eward and Fogle crossed paths briefly many years ago at Auburn University's College of Veterinary Medicine, where Eward earned his veterinary degree and Fogle spent a brief period as an intern. While they share an interest in comparative medicine, as an internist and a surgeon, their paths wouldn't necessarily have crossed again if it hadn't been for Joanne Tuohy , a veterinary surgeon now pursuing a post-doctoral PhD in Fogle's lab at NC State.

Tuohy knew from experience that dogs with osteosarcoma often die even after the tumor is removed, as the cancer spreads to distant sites. Her goal is to improve survival in her canine patients by enlisting help from the immune system. When Eward heard about what Tuohy was working on, he says his curiosity was piqued.

The team has been working together for about four years, cobbling funding together through a series of small grants from the American Kennel Club and other sources. The new funding will enable them to take the next critical steps.

"The way I look at it, osteosarcoma is this really terrible cancer—whether in a person or a dog," Eward said. "Because it's uncommon in humans, it takes a long time for us to make advances. We probably haven't made significant advances since the early 1980s and that's a travesty. What we're finding is that there are similar immune system changes that are shared between dogs with osteosarcoma and people with osteosarcoma. That's instantly exciting."

The hope is that they can find ways to coax a patient's immune system into fighting the cancer without the need for an uncontrolled infection. Eward says he's also curious to learn whether dogs and kids who go on to develop might have differences in their immune responses that make cancer more likely in the first place.

"That would be really big news if we could figure that out," he says.

Explore further: Dogs join fight against bone cancer

Related Stories

Dogs join fight against bone cancer

May 15, 2014
(HealthDay)—Man's best friend will be part of an effort to find better treatments for a type of bone cancer in children and young adults, researchers report.

Researchers say gold-based drug shows promise for fighting bone cancer in people and pets

March 26, 2014
(Medical Xpress)—A gold-based drug currently used in human and veterinary medicine to manage certain immune diseases may prove useful in combating osteosarcoma, a devastating bone cancer that affects both dogs and people, ...

Researchers study cancer in dogs to ultimately help humans with same disease

June 17, 2016
A new collaborative research program pairs oncologists who treat childhood and adult sarcomas with veterinarians who manage the same cancers in canine patients.

Gene signatures predict doxorubicin response in K9 osteosarcoma

April 20, 2015
There are two chemotherapies commonly used to treat bone cancer in dogs: doxorubicin and carboplatin. Some dogs respond better to one drug than to the other. But until now, the choice has been left largely to chance. New ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.